Xin Lang Cai Jing·2025-09-28 08:08Core Viewpoint - Nanjing Pharmaceutical has signed a strategic investment agreement with Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. and Guangzhou Guangyao Phase II Fund Equity Investment Partnership (Limited Partnership) to enhance long-term strategic cooperation and collaboration in various sectors [1] Group 1: Strategic Investment Agreement - The agreement involves Baiyunshan's subsidiary Guangyao Phase II Fund acquiring 145 million shares from the company's second-largest shareholder, Alliance Healthcare Asia Pacific Limited, representing 11.04% of the company's total share capital as of the signing date [1] - The collaboration aims to establish a stable long-term strategic partnership and deepen cooperation in capital, distribution channels for self-owned industrial products, and traditional Chinese medicine [1] Group 2: Financial Impact - The agreement does not specify a transaction amount and is not expected to have a significant impact on the company's operating performance for the current fiscal year [1]